No Joo Hwan
Institut Pasteur Korea, Leishmania Research Laboratory, 696 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea.
Acta Trop. 2016 Mar;155:113-23. doi: 10.1016/j.actatropica.2015.12.016. Epub 2015 Dec 31.
The current treatments for visceral leishmaniasis are old and toxic with limited routes of administration. The emergence of drug-resistant Leishmania threatens the efficacy of the existing reservoir of antileishmanials, leading to an urgent need to develop new treatments. It is particularly important to review and understand how the current treatments act against Leishmania in order to identify valid drug targets or essential pathways for next-generation antileishmanials. It is equally important to adapt newly emerging biotechnologies to facilitate the current research on the development of novel antileishmanials in an efficient fashion. This review covers the basic background of the current visceral leishmaniasis treatments with an emphasis on the modes of action. It briefly discusses the role of the immune system in aiding the chemotherapy of leishmaniasis, describes potential new antileishmanial drug targets and pathways, and introduces recent progress on the utilization of high-throughput phenotypic screening assays to identify novel antileishmanial compounds.
目前用于治疗内脏利什曼病的方法陈旧且有毒，给药途径有限。耐药利什曼原虫的出现威胁到现有抗利什曼病药物储备的疗效，迫切需要开发新的治疗方法。回顾和了解当前治疗方法如何对抗利什曼原虫，以确定下一代抗利什曼病药物的有效靶点或关键途径尤为重要。同样重要的是，采用新兴生物技术，以高效的方式推动当前新型抗利什曼病药物研发的研究。本综述涵盖了当前内脏利什曼病治疗方法的基本背景，重点是作用方式。简要讨论了免疫系统在利什曼病化疗中的作用，描述了潜在的新抗利什曼病药物靶点和途径，并介绍了利用高通量表型筛选试验鉴定新型抗利什曼病化合物的最新进展。
